NICE recommends Zinbryta (daclizumab high-yield process) to treat relapsing-remitting multiple sclerosis .-AbbVie + Biogen.

The National Institute for Health and Care Excellence (NICE) has published a final appraisal determination recommending Zinbryta (daclizumab high-yield process) from AbbVie + BIogen, for the treatment of adult patients living with relapsing-remitting multiple sclerosis (RRMS). However, it has stipulated that, in order to access NHS funding, the patient must have active RRMS that has previously been treated with disease-modifying therapy or rapidly evolving severe RRMS, and treatment with alemtuzumab is contraindicated or otherwise unsuitable.

Also, the advice is contingent on the continued provision of the patient access scheme, which provides a simple discount to the list price of the drug, with the discount applied at the point of purchase or invoice.